A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma
Although clinical responses were limited in the doses evaluated, dose exploration halted prematurely, making it difficult to draw definitive conclusions about the efficacy of DFF332. Further investigation is required to establish a recommended dose regimen, assess its efficacy and safety, and evaluate its full potential as a partner in combination studies.
Authors
- Filippo de Braud (ORCID: https://orcid.org/0000-0003-0103-730X)
- Mike Roy
- Shunji Takahashi (ORCID: https://orcid.org/0000-0002-5031-1953)
- Ritesh R. Kotecha (ORCID: https://orcid.org/0000-0002-0223-3479)
- Nicole Kundamal
- Joel Picus (ORCID: https://orcid.org/0000-0002-4038-936X)
- Patrizia Barzaghi-Rinaudo
- Alvin Wong (ORCID: https://orcid.org/0000-0002-2020-9624)
- Sumanta Kumar Pal (ORCID: https://orcid.org/0000-0002-1712-0848)
- Sherif Sharaby (ORCID: https://orcid.org/0009-0003-6259-4369)
- Nizar M. Tannir (ORCID: https://orcid.org/0000-0001-5559-8060)
- Peter Grell (ORCID: https://orcid.org/0000-0001-8241-0609)
- Alice Bernard‐Tessier (ORCID: https://orcid.org/0000-0001-9706-3945)
- Cristina Suárez (ORCID: https://orcid.org/0000-0002-0502-5528)
- Xin Yang (ORCID: https://orcid.org/0000-0003-4209-4220)
- Javier Otero (ORCID: https://orcid.org/0000-0002-2216-9750)
- Xin Gao (ORCID: https://orcid.org/0009-0008-2346-068X)
Institutions
- Hebron University (PS)
- Novartis (Switzerland) (CH)
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Milan (IT)
- Washington University in St. Louis (US)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Massachusetts General Hospital (US)
- National University Cancer Institute, Singapore (SG)
- City of Hope (US)
- Masaryk Memorial Cancer Institute (CZ)
- Novartis (United States) (US)
- National Cancer Institute (UA)
- Vall d'Hebron Hospital Universitari (ES)
- Center for Cancer Research (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Tris Pharma (United States) (US)
- Japanese Foundation For Cancer Research (JP)
- Novartis Institutes for BioMedical Research
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2618
- Citations
- 9
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 8.43